HiTech Pharmacal Co Newswire

HiTech Pharmacal Co Newswire

Comprehensive Real-Time News Feed for HiTech Pharmacal Co.

Results 1 - 4 of 4 in HiTech Pharmacal Co

  1. Allergan Inc Duke University v. Sandoz Inc Akorn Inc Hi Tech Pharmacal Co Inc Apotex Inc Apotex CorpRead the original story w/Photo

    Mar 21, 2017 | FindLaw

    ALLERGAN, INC., Plaintiff-Appellant DUKE UNIVERSITY, Plaintiff v. SANDOZ, INC., AKORN, INC., HI-TECH PHARMACAL CO., INC., APOTEX, INC., APOTEX CORP., Defendants-Appellees Before REYNA, WALLACH, and CHEN, Circuit Judges.CRAIG E. COUNTRYMAN, Fish & Richardson P.C., San Diego, CA, argued for plaintiff-appellant.


  2. Commvault Extends Platform Capabilities for Healthcare by Adding EHR...Read the original story

    Feb 21, 2017 | Information Technology

    Through the integration of the Commvault Data Platform with Harmony Healthcare IT's archiving solution, Health Data Archiver , healthcare customers can manage the complicated process of decommissioning legacy applicationsi 1 2by retiring Electronic Healthcare Records and Enterprise Resource Planning systems while enabling them to access and protect important clinical and business data.


  3. NYPD union goes after drug price increases amid wider pharma crackdownRead the original story w/Photo

    Nov 18, 2016 | New York Business.com

    As the generic drug industry braces for charges from a two-year U.S. Justice Department antitrust investigation, a union representing the sergeants of the New York Police Department is attempting to hit some companies with civil penalties as well. A pair of lawsuits filed by the Sergeants Benevolent Association Health & Welfare Fund against two groups of drugmakers, which include Switzerland-based Novartis AG's generic drug unit, along with Ireland-based Perrigo Co., India's Wockhardt Ltd. and Taro Pharmaceutical Industries Ltd., allege the companies colluded to raise prices on two dermatological creams as much as 1,000% starting in 2013.


  4. Investigation for Investors in Shares of Akorn, Inc. (NASDAQ:AKRX)...Read the original story w/Photo

    Nov 3, 2016 | SBWire

    An investigation for investors in shares of Akorn, Inc. was announced over potential breaches of fiduciary duties by certain directors at Akorn, Inc. Investors who purchased shares of Akorn, Inc. and currently hold any of those NASDAQ:AKRX shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554. The investigation by a law firm concerns whether certain Akorn directors breached their fiduciary duties and caused damage to the company and its shareholders.